Member Info for Laura2022

After a week consolidation at 55-59p it should be ready to push on next week, especially now the short term indicators are oversold and ready to turn positive

My target remains 95p-£1.00

Agenda at a Glance

Immunotherapy & Immuno-oncology

DAY ONE - 12 MARCH

Track 7: Discovery & Development: Cell & Combination Immunotherapies

Track 8: Biomarkers, ctDNA, Precision Medicine & Multi-Omics In Immuno-Oncology

DAY TWO - 13 MARCH

Track 7: Immunotherapy Strategies & Development

Track 8: Predictive Models, Tools & Biomarker Approaches For Pre Clinical & Clinical Evaluation & Translational Development

DAY THREE - 14 MARCH

Track 7: Novel Targets & Multi Omics Applications in Immuno-Oncology: Identification, Validation & Exploration & Personalised Cancer Therapies

This full programme for the oncology fits in with PYC software and tech? In fact PYCs Mark Davies is presenting on the 12th MRch

https://oxfordglobal.com/nextgen-biomed/events/nextgen-biomed/immunotherapy-immuno-oncology

He presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9 March 2025, 09:00 am GMT, or at any time during the live presentation.

Investors can sign up to Investor Meet Company for free and add to meet PHYSIOMICS PLC via:

https://www.investormeetcompany.com/physiomics-plc/register-investor

Investors who already follow PHYSIOMICS PLC on the Investor Meet Company platform will automatically be invited.

Genuine investors or genuine onlookers can sign up for the presentation on Monday or contact the company , the contract pipeline as states in mid 2024 will simply be more weighted towards H2 (Jan to June 2025) as opposed to being fully recognised in the results just issued ( and I was wrong thinking they'd be fully recognised and therefore I apologise, )

The company now has more than half the market value in cash and is in current contract talks for several projects

Shrimp

I'd worry more about EME

Interesting that another fishy person sushi was all over EME too

Maybe you're related

Shrimpinator

Posted in: EME

Posts: 208

Price: 0.16

No Opinion

Strong close10 Feb 2025 16:15

I might be changing my end of week projection to 0.3

You seem to have selective memory when it comes to EME QBT OBD

You were pumping QBT at 1.8p now 0.75p

You also said this about OBD which wiped out holders 5 weeks ago

One look at your posting shows us everything

Shrimpinator

Posted in: OBD

Posts: 206

Price: 0.682

No Opinion

AIm16 Jan 2025 16:00

Practically every AIM company is loss making, I am not saying bury your head in the sand and wait 10 years and everything will be rosy.

The fact remains 1 week ago there was uncertainty the company would exist, that is removed for the foreseeable future and there is lots to be done; however you could trade and make money - that's the point. Do your seriously think £7m was raised to be just dumped at .5?

Hi Ernie

You can sign up to the presentation on Monday

Hope this helps

£500k of contracts from July -Dec 2024 to be carried forward (stronger second half of the year mentioned in today's RNS)

Cash now of £700,000 v market cap £1.3mln

Charts most oversold in 12mths

Dosing tool nearly ready "final sprint"

Late stage contract

A.I medicine

TR1 buyer suggested adding more in new ISA

Clear over past 65p would be good

Stas

Make sure you keep your story straight

Moving now

Have u sold now Stas?

Just the 46 billion shares now

See RNS 07.01am 4th March

Trench

I'll be at the Q and A

Trout

I filtered him i assume he's posted 20x more than he has here than on FAB HVO

Pathetic

We’re excited to announce that the Physiomics plc team will be attending NextGen Biomed 2025 in London from 12-14 March! 🎉

Looking to de-risk the development of your therapeutic programme? At Physiomics, we specialise in providing data-driven solutions to strengthen evidence in the critical stages of drug development - from lead candidate selection and pre-clinical design to FiH starting dose and clinical dose/schedule decisions. Our goal is to help our clients make smarter, more informed decisions.

Come meet our team at NextGen Biomed and learn how our Model-Informed Drug Development expertise can optimise your drug’s journey. Whether you're developing an ADC, a multi-specific antibody, or a breakthrough immuno-oncology therapy, we’re here to help speed up your development process.

🗣️ Don’t miss Mark Davies’ presentation in the Immunotherapy & Immuno-oncology Programme on Wednesday 12th at 12:05 PM.

Yes it's a buy